Company: PFSA
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001013762-25-004396
Chunk: 2

Company: Profusa, Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1
Chunk 2
---
ieves Earnout Revenue of $99,702,000 for the fiscal year ended December 31, 2025. Amendment No. 1 also clarified the exercise price
of certain of the Company’s Warrants. 

On January 12, 2024, the
parties to the Merger Agreement entered into Amendment No. 2 to the Merger Agreement (the “Amendment”) pursuant to which
the parties agreed to revise the definition of “Milestone Event III” and such that the Earnout Revenue milestone of $11,864,000
for the fiscal year ended December 31, 2024, was replaced with a milestone requiring consummation of the Tasly JV (a joint venture contemplated
among Profusa and Tasly (International) Healthcare Capital Company Limited, as described in the Amendment) and receipt of the related
funding during the fiscal year ended December 31, 2024. . Amendment No. 2 also extended the Outside Date (the date by which the Business
Combination must be consummated, otherwise the Merger Agreement becomes terminable by Profusa or the Company) from September 21, 2023,
to June 22, 2024. 

On March 4, 2024, the parties to the Merger
Agreement entered into an Amendment No. 3 to the Merger Agreement (“Amendment No. 3 to the Merger Agreement”) pursuant
to which the parties agreed to revise the Company Reference Value to adjust for financing proceeds and debt conversions that could be
received by Profusa prior to the Business Combination. On March 14, 2024, NorthView filed a Current Report on Form 8-K regarding
Amendment No. 3 to the Merger Agreement with the SEC.

1

On February 11, 2025, the
parties to the Merger Agreement entered into an Amendment No. 4 to the Merger Agreement (“Amendment No. 4 to the Merger Agreement”)
pursuant to which the parties agreed to revise the Company Reference Value to adjust for financing proceeds that could be received by
Profusa prior to the Business Combination, along with debt conversions and incentive shares being issued that. On February 19, 2025, NorthView
filed a Current Report on Form 8-K regarding Amendment No. 4 to the Merger Agreement with the SEC.

Extension Meeting

The Company initially had
15 months from the closing of its initial